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E d tor a l
Delayed gastric emptying and prokinetic agents in continuous
ambulatory peritoneal dialysis
Since its introduction by Popovi ch and Mon crief ( I) more
than 2 decades ago , co ntinuous ambulatory peritonea l
dialysis (CAPO) has rem ained the most common form
of fir sl-linc dia lyti c Ihcrapy in Hong Kong (2) . Desp ite
its popularity, co mbati ng nutri tiona l problem s is st ill a
cha llenge to the prac ticing nephrologist (3) . Patien ts arc
often prescribed a high-protein diet to achieve nitrogen
balance. Man y patient s, however, experi ence anorexia ;
and nausea and vomiti ng after food intake is frequently
report ed in the clinic. Over time, these patient s lapse into
a sta te of malnutr it ion. which is negat ively correlated
with surv ival (4) .
An important cau se of anorexic symptom s in CAPD is
delayed gastr ic em ptying, whicb cou ld be the combined
result of increased intraperitoneal pressure co nsequ ent
upon the insti llation of dia lysi s fl uid , and auto no mic
gastropathy secondary to the underlying uremic and/or
diabetic sta te . Pre vi ou s s tud ies usin g radi onu c lide
tech niq ues that measured the gastr ic tra nsit time a fter
the ingest ion of a 99l11tcchnctium-labeled standard meal
demonstrated prolo nged ga stri e emp tyi ng in CAPD
pati ent s compared with norma l contro ls, and ga stro -
paresis is more pronounced amon g uremic diabetics (5).
To m iti gate th e c li nica l impact of gastropare si s ,
gastro intes tinal pro moti lity age nts are often pre scr ibed
to CA PO patient s. Cisapride, a serotonin receptor ago nist
with potent prok inctic propert ies originally designed for
severe gastroesophageal refl ux disease, is one of the most
frequ ently used age nts amo ng CA PD patient s in the past
decade. The c linica l efficacy of ci sapride has heen
docu mented in one study, which reported inc reased
plasma albumin level s after treatm ent in persistently
hypoalhuminemic chron ic dia lysis patients who had poor
gastric empt ying (6).
In 1995, 2 years a fter its approval by the US Food and
Drug Admi nistrat ion (F DA), tbe re were "black box"
warnings that ci sapride (Propu lsid ®) could ca use life -
threa teni ng ca rd iac arrh yt hmias , notably torsades de
poi nt e s . in pati en ts sus ce pt ib le e ithe r beca use of
co nc urre nt med icat ion s that inter fere wi th ci sap ride
metabolism or prolong the QT interval or because of other
di sease s tha t pred ispo se to suc h arrhyt hmias . Th e se
wa rnings, together witb subse quent health alert s issued
by the manufacturer, led to regulatory action in 1998 by
the FDA that contraindicated the Li se of cisapride in such
patients (7) . Fur tber data from the FDA Talk Paper TOO-
14 (8), wh ich ind icat ed that as 01" December 3 1, 1999,
use of ci sapri de wa s asso cia ted with 34 1 re ports of
arr hy thm ia s an d 80 report s of deat h, prompt ed its
complete wit hdrawal from the US market in July 2000.
Perhaps the vig ilant reader wou ld have noted that the
wi thdrawa l of ci sa pride in the US was not ent ire ly
ev idence-based . A recen t study conducted in children on
per itonea l d ialysis foun d mild hut significant inc reases
in QTc inte rval s, whi eb were mostl y attr ibuted to
co ncomitant medications rather than cisapridc per se (9).
Whether cisapride is safe in the adult dialysis pop ulatio n
remai ns largely unknown. In this issue of the Hong Kong
Joumal 01" Ncphrology, Tsc cl al ( 10) addressed this issue
by retrospectively comparing the clinical outcom e of S5
chronic di a lysis patients who had rece ived cisapride
versus that of 279 patients who had never taken cisaprid c.
Thc au thors found that the usc of cisapride, regardless
o f do sage , docs not increase morta lity. Ne vertheless.
hypoalbum inem ia and hypokalemia were ide ntified as
independent predictors of mortality in patients who had
taken ci sapride, Ironically, hypoalbum inemia could well
he the very reason fo r prescribing a prokinctic agen t for
these patients in the first place. Jknee. the clinician must
ex ercise his ow n ac ume n by taking the appropriate
preca utio na ry measures which , as Tse et al have also
partly poi nted ou t, incl ude (a) ca utiou s reapprai sa l of
the ind ication of cisap ride : (b) detect ion of unrecognized
underlying card iac disease or QT interval prolongation ;
(e) co rrec t ion of a ny pro-arrhyt hmi c e lec t ro ly te
d isturba nces before prescription; (d}judicious review of
co ncomi tan t me d icat io ns that may int eract w it h
ci sapridc; (e) serial mon itoring of the QT interv al and
serum potassium leve l after co mmenci ng treatment ; and
(f) co nstant evaluation of the ind icat ion of co nti nuing
tbe prescript ion .
W here arc th e potent ia l pitfall s in pharm aco log ic
interac tion? In ge ne ra l , c isapride mu st not be co-
ad mini stcred wi th agen ts that possess e ither of the
followin g two major pharmacok inetic/pharmacodynamie
propert ies : (a) inhibi tors of cy tochrome P450-3A4
en zyme s (C Y P-3A4) suc h as macro lides ( I I ), new
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antidepressants particularly nefazodone and fluvoxarnine
( 12), azo le antimycot ics, dilti azem , cimetadine, and
isoniazid. The rationale is that CYP-3A4 is the primary
mode of cisapride metabolism. As such, attention must
a lso be d rawn to t he rece nt ide n t ificat io n o f
epoxy bergamott in as a CYP-3A4 inhibitor in grapefruit
( 13); and (b) drugs with arrbytbmoge nie poten tial that
prolong the QT interval. such as class la/III (by Vaughan
Will iam s cl ass ifi c ati on ) a nt iarrhyt h mic drugs
particularly sotalol (14), and the second-generation non-
seda tive selective HI-receptor antihistamines such as
loratadin e, terfenadine, astem izole (15) . The rationale
is th at these dru gs share the same arrhyt hmoge nic
mecb ani sm with c isupridc in QT prol on gati on by
spec ific. high affinity blockade of the cardiac K+channel
encoded by the buman ether-a-go-go-related gene (HERO)
in chromosome 7 ( 16).
What is the current status in Hong Kong? Following the
withdrawa l of c isa pride in the US, a "Prcpulsid!
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(Cisa pri de) L im ited Acce s s Pr ogramm e " wa s
impl emented in June 200 I to prevent potent ially fatal
event s rel at ed to c isapr ide usage. T he mandatory
Programme Form that includes a thorou gh checklist of
co ntraindications mu st be signed by the phys ician,
prefera bly a gas troe ntero log is t, and th e pa tient in
quadruplicate to be retained by the institution/clinic in
the patient 's medical record, the pha rmacy. the dr ug
supplier. and the patient. It is not surpris ing that after
the enforcement of such stringent procedures. cisapride
has become almo st an exti nct item in thi s locality.
Alternative prokin etic agents that the neph rologist may
co nsider include do rnperido ne, rnetoclopramide, and
ery thromyci n. The ideal prokine tic agent- on e that
restores gas tric motility without compro mising cardiac
HERO ch ann el s and docs not depend on CYP-3A 4
eliminatio n- has yet to be form ulated.
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